View Item 

Show simple item record

Long-Term Effects of a Losartan-Compared With an Atenolol-Based Treatment Regimen on Carotid Artery Plaque Development in Hypertensive Patients With Left Ventricular Hypertrophy: ICARUS, a LIFE Substudy

dc.contributor.authorFossum, Eigilen_US
dc.contributor.authorOlsen, Michael Hechten_US
dc.contributor.authorHøieggen, Auden_US
dc.contributor.authorWachtell, Kristianen_US
dc.contributor.authorReims, Henrik M.en_US
dc.contributor.authorKjeldsen, Sverre E.en_US
dc.contributor.authorIbsen, Hansen_US
dc.contributor.authorWan, Yingen_US
dc.contributor.authorJulius, Stevoen_US
dc.date.accessioned2010-06-01T20:01:53Z
dc.date.available2010-06-01T20:01:53Z
dc.date.issued2006-03en_US
dc.identifier.citationFossum, Eigil; Olsen, Michael Hecht; HØieggen, Aud; Wachtell, Kristian; Reims, Henrik M . ; Kjeldsen, Sverre E . ; Ibsen, Hans; Wan, Ying; Julius, Stevo (2006). "Long-Term Effects of a Losartan-Compared With an Atenolol-Based Treatment Regimen on Carotid Artery Plaque Development in Hypertensive Patients With Left Ventricular Hypertrophy: ICARUS, a LIFE Substudy." The Journal of Clinical Hypertension 8(3): 169-173. <http://hdl.handle.net/2027.42/73158>en_US
dc.identifier.issn1524-6175en_US
dc.identifier.issn1751-7176en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73158
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16522993&dopt=citationen_US
dc.format.extent162313 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherLe Jacq Ltd.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.rights2006 Le Jacq Ltd.en_US
dc.titleLong-Term Effects of a Losartan-Compared With an Atenolol-Based Treatment Regimen on Carotid Artery Plaque Development in Hypertensive Patients With Left Ventricular Hypertrophy: ICARUS, a LIFE Substudyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Hypertension, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MIen_US
dc.contributor.affiliationotherFrom the Departments of Cardiologyen_US
dc.contributor.affiliationotherNephrology,en_US
dc.contributor.affiliationotherUllevaal University Hospital, Oslo, Norway; the Departments of Clinical Physiology and Nuclear Medicineen_US
dc.contributor.affiliationotherInternal Medicine,en_US
dc.contributor.affiliationotherGlostrup University Hospital, Glostrup, Denmark; Merck Research Laboratories, Blue Bell, PA;en_US
dc.identifier.pmid16522993en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73158/1/j.1524-6175.2006.04838.x.pdf
dc.identifier.doi10.1111/j.1524-6175.2006.04838.xen_US
dc.identifier.sourceThe Journal of Clinical Hypertensionen_US
dc.identifier.citedreferenceLewington S, Clarke R, Qizilbash N, et al., For the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903 – 1913.en_US
dc.identifier.citedreferenceEzzati M, Lopez AD, Rodgers A, et al., For the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002; 360: 1347 – 1360.en_US
dc.identifier.citedreferenceKjeldsen SE, Westheim AS, Os I. INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study. Lancet. 2000; 356: 1929 – 1930.en_US
dc.identifier.citedreferenceDahl?f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995 – 1003.en_US
dc.identifier.citedreferenceOlsen MH, Fossum E, Hjerkinn E, et al. Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE substudy. Insulin Carotids US Scandinavia. J Hypertens. 2000; 18: 75 – 81.en_US
dc.identifier.citedreferenceOlsen MH, Fossum E, H?ieggen A, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens. 2005; 23: 891 – 898.en_US
dc.identifier.citedreferenceOlsen MH, Wachtell K, Neland K, et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press. 2005; 14: 177 – 183.en_US
dc.identifier.citedreferenceHollander M, Bots ML, Del Sol AI, et al. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: the Rotterdam study. Circulation. 2002; 105: 2872 – 2877.en_US
dc.identifier.citedreferenceBrasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002; 22: 1257 – 1266.en_US
dc.identifier.citedreferenceSun YP, Zhu BQ, Browne AE, et al. Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther. 2001; 6: 175 – 181.en_US
dc.identifier.citedreferenceSchiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000; 101: 1653 – 1659.en_US
dc.identifier.citedreferenceWiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002; 33: 572 – 577.en_US
dc.identifier.citedreferenceHoward G, Sharrett AR, Heiss G, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC investigators. Stroke. 1993; 24: 1297 – 1304.en_US
dc.identifier.citedreferenceKlemsdal TO, Moan A, Kjeldsen SE. Effects of selective angiotensin II type 1 receptor blockade with losartan on arterial compliance in patients with mild essential hypertension. Blood Press. 1999; 8: 214 – 219.en_US
dc.identifier.citedreferenceSchieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000; 101: 1372 – 1378.en_US
dc.identifier.citedreferenceKr?mer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res. 2002; 90: 770 – 776.en_US
dc.identifier.citedreferenceSpence JD. Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol. 2002; 89 ( 4A ): 10B – 16B.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1524-6175.2006.04838.x.pdf
Size:
158.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.